Skip to main content
Premium Trial:

Request an Annual Quote

Abbott and Caprion Sign Research Deal for Lung Cancer Targets

NEW YORK, Feb. 4 (GenomeWeb News) - Caprion Pharmaceuticals and Abbott Laboratories will collaborate on lung cancer antibody drug targets, the companies said today.


Abbott will evaluate a number of Caprion's cell surface drug targets for non-small-cell lung cancer, and plans to add additional targets from an ongoing Caprion project. In its research, Caprion has been applying its CellCarta proteomics approach, comparing plasma membrane proteins from normal and cancer tissue samples.


Abbott will obtain exclusive worldwide rights to develop selected targets and commercialize drugs that target them.


Under the agreement, Caprion will receive an upfront payment, milestone payments, and royalties from future product sales.


Last year, Montreal-based Caprion Pharmaceuticals signed research collaborations with  AstraZeneca and  Wyeth.



The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.